Low Antibiotic Resistance of <i>Helicobacter pylori</i> in The Netherlands

Mourad-Baars, P. E. C.; Wunderink, Herman F.; Mearin, M. L.; Veenendaal, R. A.; Wit, Jan M.; Veldkamp, Karin Ellen

doi:10.1111/hel.12175

Cited by 7 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…pylori isolates to metronidazole was extremely high in our study (68.8%), especially 80.6% in 2014. It was higher than that in most countries and was approximate to it in some certain areas of China, and even in adults . The global resistance rate was high in China because of the overuse of metronidazole.…”

Section: Discussionmentioning

confidence: 83%

Antibiotics resistance of Helicobacter pylori in children with upper gastrointestinal symptoms in Hangzhou, China

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 83%

Antibiotics resistance of Helicobacter pylori in children with upper gastrointestinal symptoms in Hangzhou, China

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In Turkey, Kocazeybek et al reported resistance rates of 24.86,33.75,23.77,3.51, and 0.97% for clarithromycin, metronidazole, levofloxacin, tetracycline and amoxicillin, respectively (Kocazeybek and Tokman, 2016). In contrast to the rising tendency of Hp multi-resistance to antibiotics observed in most European countries, Mourad-Baars et al reported remarkably low rates of Hp antibiotic resistance in the Netherlands, particularly for clarithromycin and metronidazole (Mourad-Baars et al, 2015).…”

Section: Prevalence Of Mdrmentioning

confidence: 99%

Multidrug resistance in Helicobacter pylori infection

et al. 2023

View full text Add to dashboard Cite

Helicobacter pylori (Hp), a well-known human pathogen, causes one of the most common chronic bacterial infections and plays an important role in the emergence of chronic progressive gastric inflammation and a variety of gastrointestinal diseases. The prevalence of Hp infection varies worldwide and is indirectly proportional to socio-economic status, especially during childhood. The response to the eradication therapy significantly depends on the antibiotic resistance specific to each geographical region; thus, currently, given the increasing prevalence of antimicrobial resistance (especially to clarithromycin, metronidazole, and levofloxacin), successful treatment for Hp eradication has become a real challenge and a critical issue. The most incriminated factors associated with multidrug resistance (MDR) in Hp proved to be the overuse or the improper use of antibiotics, poor medication adherence, and bacterial-related factors including efflux pumps, mutations, and biofilms. Up to 30% of first-line therapy fails due to poor patient compliance, high gastric acidity, or high bacteremia levels. Hence, it is of great importance to consider new eradication regimens such as vonoprazan-containing triple therapies, quintuple therapies, high-dose dual therapies, and standard triple therapies with probiotics, requiring further studies and thorough assessment. Strain susceptibility testing is also necessary for an optimal approach.

show abstract

“…Kocazeybek et al summarized the prevalence of primary H. pylori antimicrobial resistance in Turkey, and the results showed that the resistance rates were 24.86% for clarithromycin, 33.75% for metronidazole, 23.77% for levofloxacin, 0.97% for amoxicillin and 3.51% for tetracycline (Kocazeybek and Tokman, 2016). Low H. pylori antibiotic resistance was observed in the Netherlands despite the increasing trend of H. pylori resistance to antibiotics identified in most European countries (Mourad-Baars et al, 2015). In two prospective, multicenter molecular studies conducted in Algeria and Morocco regarding primary H. pylori resistance to clarithromycin (Bouilhat et al, 2015; Djennane-Hadibi et al, 2016), both studies reported high levels of H. pylori resistance to clarithromycin (33% in Algeria and 28.2% in Morocco), which indicated that standard clarithromycin-based triple therapies should not be considered as first-line treatments for H. pylori in these countries.…”

Section: Helicobacter Pylori Recurrencementioning

confidence: 99%

Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance

Zhu

Lü

2017

Front. Cell. Infect. Microbiol.

131

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a common gastrointestinal bacterial strain closely associated with the incidence of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. A current research and clinical challenge is the increased rate of antibiotic resistance in H. pylori, which has led to a decreased H. pylori eradication rate. In this article, we review recent H. pylori infection and reinfection rates and H. pylori resistance to antibiotics, and we discuss the pertinent treatments. A PubMed literature search was performed using the following keywords: Helicobacter pylori, infection, reinfection, antibiotic resistance, bismuth, proton pump inhibitors, vonoprazan, susceptibility, quintuple therapy, dual therapy, and probiotic. The prevalence of H. pylori has remained high in some areas despite the decreasing trend of H. pylori prevalence observed over time. Additionally, the H. pylori reinfection rate has varied in different countries due to socioeconomic and hygienic conditions. Helicobacter pylori monoresistance to clarithromycin, metronidazole or levofloxacin was common in most countries. However, the prevalence of amoxicillin and tetracycline resistance has remained low. Because H. pylori infection and reinfection present serious challenges and because H. pylori resistance to clarithromycin, metronidazole or levofloxacin remains high in most countries, the selection of an efficient regimen to eradicate H. pylori is critical. Currently, bismuth-containing quadruple therapies still achieve high eradication rates. Moreover, susceptibility-based therapies are alternatives because they may avoid the use of unnecessary antibiotics. Novel regimens, e.g., vonoprazan-containing triple therapies, quintuple therapies, high-dose dual therapies, and standard triple therapies with probiotics, require further studies concerning their efficiency and safety for treating H. pylori.

show abstract

Low Antibiotic Resistance of Helicobacter pylori in The Netherlands

Cited by 7 publications

References 6 publications

Antibiotics resistance of Helicobacter pylori in children with upper gastrointestinal symptoms in Hangzhou, China

Antibiotics resistance of Helicobacter pylori in children with upper gastrointestinal symptoms in Hangzhou, China

Multidrug resistance in Helicobacter pylori infection

Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance

Contact Info

Product

Resources

About